Our scientists have been working hard to develop an antigen-specific T cell line directed against the spike protein of SARS-CoV-2, the virus that causes COVID-19. The line is now available on our website for purchase.
Preliminary studies, such as this one in Cell, suggest a T cell defense against COVID-19 found in infected individuals and in those not known to be infected — likely from a previous infection of another coronavirus.
In Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals, Grifoni et al. describe:
- Measuring immunity to SARS-CoV-2 is key to understanding COVID-19 and vaccine development
- Epitope pools detect CD4+ and CD8+ T cells in 100% and 70% of convalescent COVID patients
- T cell responses are focused not only on spike but also on M, N, and other ORFs
- T cell reactivity to SARS-CoV-2 epitopes is also detected in non-exposed individuals
COVID-19-Specific T Cells for Vaccine Development and Research
Our new COVID-19-specific T cell line is HLA*0201-restricted and recognizes the epitope at residues 424–433 and is 90% identical to the corresponding region of SARS.
The donor is healthy and not known to be positive for novel coronavirus.
The anti-SARS-CoV-2 T cells will lyse cells that are given the peptide. While we predict these antigen-specific T cells will lyse infected cells, this has not yet been confirmed.
With over 100 vials in stock, you can purchase a small amount or large batch to support your coronavirus research and development efforts.
Not Back in the Lab Yet?
Contact us to reserve your COVID-19-specific T cells for when you’re back to work.